TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34011410

Group type: EXPERIMENTAL
Intervention: Evidence-based interventions (EBIs) including improvement of patient education materials, provision of provider education, enhancement of electronic health record (EHR) systems, development of clinic screening protocols, and implementation of community CRC awareness events.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinics' individually tailored multilevel interventions (MLIs) addressing barriers at patient, provider, clinic, and community levels.
Number of subjects: 0
Study: 34011535

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Apatinib
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Genomic profiling (targeted next-generation sequencing of 425 cancer-related genes)
Number of subjects: 32
Study: 34011601

Group type: EXPERIMENTAL
Intervention: Teleconsultation (TeleNS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: In-person examination
Number of subjects: 100
Study: 34011634

Group type: EXPERIMENTAL
Intervention: Risk-prediction model for pediatric HA-VTE
Number of subjects: 111352
Study: 34011835

Group type: EXPERIMENTAL
Intervention: Myocardial Resting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myocardial Revascularization
Number of subjects: 0
Study: 34011995

Group type: EXPERIMENTAL
Intervention: HER2 blockade treatment, specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34012367

Group type: EXPERIMENTAL
Intervention: Alpelisib
Number of subjects: 8
Study: 34012418

Group type: EXPERIMENTAL
Intervention: Intensive training for upper extremity function, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34012620

Group type: EXPERIMENTAL
Intervention: Confocal endomicroscopy
Number of subjects: 36
Study: 34012780

Group type: EXPERIMENTAL
Intervention: Flexible bronchoscopy (FB) examination
Number of subjects: 615

Group type: COMPARATOR
Intervention: Surgical intervention (thoracoscopic or open surgery)
Number of subjects: 615
Study: 34012920

Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg per day for a cycle of 28 days)
Number of subjects: 32
Study: 34013092

Group type: EXPERIMENTAL
Intervention: hs-cTnI pathway
Number of subjects: 11070
Study: 34013094

Group type: EXPERIMENTAL
Intervention: Setmelanotide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 34013139

Group type: EXPERIMENTAL
Intervention: Endoluminal negative pressure (ENP) therapy via polyurethane foam (EsoSponge)
Number of subjects: 40
Study: 34013143

Group type: EXPERIMENTAL
Intervention: ReHub telerehabilitation system
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fast Track recovery protocol (control group)
Number of subjects: 52
Study: 34013182

Group type: EXPERIMENTAL
Intervention: VCX stent grafts underdilated to 8 mm
Number of subjects: 114

Group type: COMPARATOR
Intervention: VTS stent grafts underdilated to 8 mm
Number of subjects: 114
Study: 34013252

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 100
Study: 34013254

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34013257

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34013386

Group type: EXPERIMENTAL
Intervention: Japanese TTS patients
Number of subjects: 2173

Group type: COMPARATOR
Intervention: European TTS patients
Number of subjects: 2173
Study: 34013498

Group type: EXPERIMENTAL
Intervention: Herpes zoster (HZ) patients without complications
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Herpes zoster (HZ) patients with postherpetic neuralgia (PHN)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Overall cohort of herpes zoster (HZ) patients
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Herpes zoster (HZ) patients
Number of subjects: 545
Study: 34013619

Group type: COMPARATOR
Intervention: Sphenopalatine ganglion block
Number of subjects: 0
Study: 34013969

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 48509
Study: 34014326

Group type: EXPERIMENTAL
Intervention: EHR-integrated screening at any visit
Number of subjects: 93114

Group type: EXPERIMENTAL
Intervention: Self-administered screening approach
Number of subjects: 93114

Group type: EXPERIMENTAL
Intervention: Robust practice facilitation and EHR usability testing
Number of subjects: 93114

Group type: COMPARATOR
Intervention: Annual examinations only
Number of subjects: 93114

Group type: COMPARATOR
Intervention: Staff-administered screening approach
Number of subjects: 93114

Group type: EXPERIMENTAL
Intervention: All clinics
Number of subjects: 93114
Study: 34014429

Group type: EXPERIMENTAL
Intervention: Group Intervention (GI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual Counselling (IC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collective Advocacy (CA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 0
Study: 34014549

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 222
Study: 34014839

Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS)
Number of subjects: 12353

Group type: EXPERIMENTAL
Intervention: GWAS of oxidative hemolysis
Number of subjects: 12353

Group type: EXPERIMENTAL
Intervention: Testing of genome-wide significant loci
Number of subjects: 12353
Study: 34015091

Group type: EXPERIMENTAL
Intervention: High-resolution peripheral quantitative CT (HR-pQCT) of two metacarpophalangeal (MCP) joints
Number of subjects: 353

Group type: COMPARATOR
Intervention: Conventional radiography (CR) of 44 joints
Number of subjects: 353
Study: 34015096

Group type: EXPERIMENTAL
Intervention: Surgically closed ASD
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Percutaneously closed ASD
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 53
Study: 34015112

Group type: EXPERIMENTAL
Intervention: SPUM-ACS Score
Number of subjects: 2168

Group type: COMPARATOR
Intervention: GRACE 2.0 Score
Number of subjects: 2168
Study: 34015141

Group type: COMPARATOR
Intervention: Internet-based cognitive and behavioural therapy (I-C/BT) with therapist guidance
Number of subjects: 808

Group type: COMPARATOR
Intervention: Internet-based cognitive and behavioural therapy (I-C/BT)
Number of subjects: 808
Study: 34015791

Group type: EXPERIMENTAL
Intervention: Focal Electrically Administered Seizure Therapy (FEAST)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ultrabrief Pulse Right Unilateral Electroconvulsive Therapy (UB-RUL ECT)
Number of subjects: 39
Study: 34016140

Group type: EXPERIMENTAL
Intervention: Meals consumed at home
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meals consumed away from home
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meals eaten with company
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meals eaten without company
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meals with screen time
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meals without screen time
Number of subjects: 0
Study: 34016182

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 7
Study: 34016423

Group type: EXPERIMENTAL
Intervention: Surgical revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrid revascularization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34016561

Group type: EXPERIMENTAL
Intervention: Ibudilast (MN-166), dosage and duration not specified
Number of subjects: 0
Study: 34016656

Group type: EXPERIMENTAL
Intervention: United States cohort
Number of subjects: 0

Group type: COMPARATOR
Intervention: Canadian cohort
Number of subjects: 0
Study: 34016873

Group type: EXPERIMENTAL
Intervention: High pancreatic enzyme replacement therapy (PERT) dosing (>2000 lipase units/kg per meal)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Use of acid suppressive medications
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: High levels of fecal calprotectin (fCP) (>200 μg/g)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Higher relative abundance of fecal Klebsiella pneumoniae
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: GI-related hospitalization
Number of subjects: 231
Study: 34016877

Group type: EXPERIMENTAL
Intervention: Maternal Obesity (MO)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Normal-Weight Mothers (NWM)
Number of subjects: 221
Study: 34016879

Group type: EXPERIMENTAL
Intervention: BSEP deficiency (n=53, including 8 with biallelic truncating mutations and 10 with mild mutations)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: FIC1 deficiency (n=26)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: MDR3 deficiency (n=19, including four monoallelic)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: surgical interruption of enterohepatic circulation (sEHC)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: liver transplant (LT) after sEHC
Number of subjects: 98
Study: 34017073

Group type: EXPERIMENTAL
Intervention: 10 mg ruxolitinib b.i.d. for the first 12 weeks, then up-titrations of up to 25 mg b.i.d. based on efficacy and platelet counts
Number of subjects: 51
Study: 34017263

Group type: EXPERIMENTAL
Intervention: Norepinephrine treatment
Number of subjects: 0
Study: 34017270

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34017617

Group type: EXPERIMENTAL
Intervention: Leg press and hip abduction maximal strength training (MST) 3 times per week for 8 weeks, using heavy loads (85-90% of 1 repetition maximum; 1RM) and 4-5 repetitions in 4 sets.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional physiotherapy (CG) for 8 weeks.
Number of subjects: 21
Study: 34017848

Group type: EXPERIMENTAL
Intervention: Dynamic Hyperinflation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 34017869

Group type: EXPERIMENTAL
Intervention: Handheld ECG tracking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard monitoring)
Number of subjects: 0
Study: 34018141

Group type: EXPERIMENTAL
Intervention: CRP on postoperative day 5
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CRP results ≥ 15.3 mg/dL on day 3
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CRP results ≥ 9.1 mg/dL on day 5
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Normal CRP and PCT values
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CRP and PCT on days 3 and 5
Number of subjects: 95
Study: 34019108

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg daily from Days 9-18
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg daily from Days 9-18
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fedratinib 500 mg on Day 1 and Day 17
Number of subjects: 0
Study: 34019229

Group type: EXPERIMENTAL
Intervention: Continuing risankizumab treatment
Number of subjects: 336

Group type: COMPARATOR
Intervention: Withdrawing from risankizumab treatment
Number of subjects: 336
Study: 34019439

Group type: EXPERIMENTAL
Intervention: Beach Chair Position (BC)
Number of subjects: 714

Group type: COMPARATOR
Intervention: Lateral Decubitus Position (LD)
Number of subjects: 714
Study: 34019468

Group type: EXPERIMENTAL
Intervention: PCV13 followed by PPSV23 (8 weeks later)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV13 followed by PPSV23 (26 weeks later)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPSV23 (8 weeks after PCV13)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPSV23 (26 weeks after PCV13)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPSV23 (8 weeks or 26 weeks after PCV13)
Number of subjects: 0
Study: 34019698

Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) as perioperative treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) alone as perioperative treatment.
Number of subjects: 0
Study: 34020114

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34020147

Group type: EXPERIMENTAL
Intervention: Intraoperative electrocorticography (ECoG) guided extended lesionectomy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Residual epileptic waves detected by intraoperative ECoG
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Concomitant focal cortical dysplasia (FCD)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Patients with CRE without FCD
Number of subjects: 85
Study: 34020272

Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 0
Study: 34020607

Group type: EXPERIMENTAL
Intervention: Combined RNA + DNA extraction method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: emm75 qPCR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional separate RNA-only and DNA-only extractions
Number of subjects: 0
Study: 34020637

Group type: EXPERIMENTAL
Intervention: Capnography-based predictive model for FEV1
Number of subjects: 160

Group type: COMPARATOR
Intervention: Spirometry (gold standard)
Number of subjects: 160
Study: 34020658

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 19960
Study: 34020900

Group type: EXPERIMENTAL
Intervention: Orbital atherectomy (OA) via transradial access (TRA) followed by balloon angioplasty
Number of subjects: 50
Study: 34021063

Group type: EXPERIMENTAL
Intervention: Low weight-for-height (WHZ) only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low WHZ
Number of subjects: 0
Study: 34021573

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee consumption (1-7 cups/week)
Number of subjects: 25462

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee consumption (>1 cup/day)
Number of subjects: 25462

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee consumption (1-7 cups/week) in meta-analysis of both cohorts
Number of subjects: 25462

Group type: COMPARATOR
Intervention: Caffeinated coffee consumption (≤3 cups/month)
Number of subjects: 25462
Study: 34021827

Group type: EXPERIMENTAL
Intervention: Rapid antigen tests (RATs) for SARS-CoV-2; tested three times per week for two weeks.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Reverse transcription polymerase chain reaction (RT-PCR); tested concurrently with RATs.
Number of subjects: 36
Study: 34021886

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel for pALL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel for DLBCL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 0
Study: 34022160

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34022380

Group type: EXPERIMENTAL
Intervention: CTAG device
Number of subjects: 66
Study: 34022621

Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray
Number of subjects: 175
Study: 34022698

Group type: EXPERIMENTAL
Intervention: Immune-checkpoint inhibitors (ICI)
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1485
Study: 34022795

Group type: EXPERIMENTAL
Intervention: GSH-CBT guided by lay providers (LPs)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: GSH-CBT guided by LPs
Number of subjects: 90
Study: 34022802

Group type: EXPERIMENTAL
Intervention: High somatization (HS) group
Number of subjects: 47

Group type: COMPARATOR
Intervention: Low somatization (LS) group
Number of subjects: 47
Study: 34022805

Group type: EXPERIMENTAL
Intervention: HATMD (present)
Number of subjects: 185
Study: 34022813

Group type: EXPERIMENTAL
Intervention: Pure-Vu System
Number of subjects: 94
Study: 34022820

Group type: EXPERIMENTAL
Intervention: Quarterly HIV prevention services including clinical examination, HIV testing, screening and treatment for other sexually transmitted infections, peer-led counselling and support, provision of condoms and lubricants.
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Quarterly HIV prevention services
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Quarterly follow-up visits
Number of subjects: 618
Study: 34022826

Group type: EXPERIMENTAL
Intervention: GLA:D® Back programme (10-week programme consisting of 2 educational and 16 supervised exercise sessions)
Number of subjects: 1730

Group type: EXPERIMENTAL
Intervention: GLA:D® Back programme
Number of subjects: 1730
Study: 34022955

Group type: EXPERIMENTAL
Intervention: LEAP-MS intervention (tailored blended physiotherapy intervention with online platform)
Number of subjects: 21
Study: 34022988

Group type: EXPERIMENTAL
Intervention: Critical care interventions (including respiratory support such as high flow oxygenation, continuous positive airway pressure, invasive mechanical ventilation)
Number of subjects: 3140

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 3140

Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 3140
Study: 34023224

Group type: EXPERIMENTAL
Intervention: NIA-AA criteria with comprehensive neuropsychological evaluation
Number of subjects: 431

Group type: COMPARATOR
Intervention: DSM-5 criteria with cognitive screener
Number of subjects: 431
Study: 34023254

Group type: EXPERIMENTAL
Intervention: Cardiovascular Magnetic Resonance at 0.55-T
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiovascular Magnetic Resonance at 1.5-T
Number of subjects: 0
Study: 34023255

Group type: EXPERIMENTAL
Intervention: Poststent OCT findings with significant malapposition (TMV ≥7.0 mm)
Number of subjects: 1290

Group type: COMPARATOR
Intervention: Suboptimal OCT findings (not specified)
Number of subjects: 1290
Study: 34023265

Group type: EXPERIMENTAL
Intervention: Glycemic control intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 34023270

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: PCI with pre-PCI FFR ≤0.8 and post-PCI FFR >0.8
Number of subjects: 538

Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 538
Study: 34023350

Group type: EXPERIMENTAL
Intervention: 6-week course of sofosbuvir-velpatasvir (short arm, n=93)
Number of subjects: 188

Group type: COMPARATOR
Intervention: 12-week course of sofosbuvir-velpatasvir (standard arm, n=95)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 6-week course of sofosbuvir-velpatasvir (modified ITT analysis)
Number of subjects: 188

Group type: COMPARATOR
Intervention: 12-week course of sofosbuvir-velpatasvir (modified ITT analysis)
Number of subjects: 188
Study: 34023558

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 141
Study: 34023735

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 7698

Group type: EXPERIMENTAL
Intervention: Severe anemia
Number of subjects: 7698

Group type: COMPARATOR
Intervention: No anemia
Number of subjects: 7698
Study: 34024024

Group type: EXPERIMENTAL
Intervention: Late-onset ATTRv Val30Met amyloidosis
Number of subjects: 1389

Group type: COMPARATOR
Intervention: Early-onset ATTRv Val30Met amyloidosis
Number of subjects: 1389
Study: 34024025

Group type: EXPERIMENTAL
Intervention: Gocovri
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 34024120

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34024501

Group type: EXPERIMENTAL
Intervention: Clinical nutrition support during ICU stay
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Data collection from ICU day 1-4 and prospective observation from day 5-90
Number of subjects: 1250
Study: 34024522

Group type: EXPERIMENTAL
Intervention: Red Bull energy drink (25 cl)
Number of subjects: 20
Study: 34024757

Group type: EXPERIMENTAL
Intervention: Combined coronary CT angiography (CTA) and myocardial CT perfusion imaging (CTP)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA) and single photon emission tomography (SPECT)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Combined CTA-CTP
Number of subjects: 381

Group type: COMPARATOR
Intervention: Combined ICA-SPECT
Number of subjects: 381
Study: 34025448

Group type: EXPERIMENTAL
Intervention: Photoplethysmography (PPG) features including five pulse interval variability, four amplitude features, and a novel autocorrelation-based morphology feature.
Number of subjects: 359
Study: 34025640

Group type: EXPERIMENTAL
Intervention: Intracranial and systemic immunoadjuvants with low-dose reirradiation
Number of subjects: 30
Study: 34025651

Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 0
Study: 34025681

Group type: EXPERIMENTAL
Intervention: Low-dose lenalidomide plus dexamethasone
Number of subjects: 41
Study: 34025756

Group type: EXPERIMENTAL
Intervention: First-step screening with brief tests covering PICS domains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second extended assessment if indicated
Number of subjects: 0
Study: 34026647

Group type: EXPERIMENTAL
Intervention: CAR T-EGFRvIII cells
Number of subjects: 1
Study: 34026778

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) as an adjunct therapy for COVID-19
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-invasive transcutaneous vagal nerve stimulation (t-VNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacological strategies (e.g., tocilizumab, corticosteroids)
Number of subjects: 0
Study: 34026784

Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR-T cell therapy followed by haploidentical hematopoietic stem cell transplantation (haploidentical-HSCT)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR-T cell therapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Number of subjects: 1
Study: 34027223

Group type: EXPERIMENTAL
Intervention: Health system intervention combined with an aspirin awareness media campaign
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 267
Study: 34027291

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg daily)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 105
Study: 34027296

Group type: EXPERIMENTAL
Intervention: Anemia and vitamin B-12 and folate status assessment in women of reproductive age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predicted NTD prevalence based on RBC folate concentrations
Number of subjects: 0
Study: 34027757

Group type: EXPERIMENTAL
Intervention: Peer-befriending intervention comprising six visits over three months with training and ongoing supervision.
Number of subjects: 10